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Introduction {#sec1}
============

Considerable efforts have been made to identify the gene networks that regulate the pluripotent state and control the first steps of differentiation, when cells start to acquire a cell-lineage-specific identity. These studies have identified key transcriptional regulatory networks that determine the pluripotent state ([@bib17]). In contrast, we know relatively little about how different organelles, such as mitochondria, adapt to the changing environments they encounter during differentiation and reprogramming. While increased mitochondrial fragmentation is a fundamental feature of reprogramming ([@bib29]), the molecular mechanisms underlying this phenomenon are not fully understood.

The mitochondrial dynamics machinery is composed of dynamin superfamily guanosine triphosphatases (GTPases) that have roles in either fission (division) or fusion of mitochondria. Dynamin-related protein 1 (DRP-1) is required for mitochondrial fission. DRP-1 activation is mediated in part by phosphorylation, ubiquitination, and sumoylation, which allow for increased recruitment to various receptors (e.g., FIS1) ([@bib34]). However, these mechanisms of enhanced DRP-1 recruitment to the outer mitochondrial membrane are not well characterized in pluripotent stem cells (PSCs), where they appear to be constitutively active. Once activated, DRP-1 forms oligomers and assembles into rings that constrict around the mitochondria, dividing the organelle into separate entities ([@bib35]). Fusion is mediated through the activity of the optic atrophy type 1 (OPA1) GTPase at the inner mitochondrial membrane and of mitofusins (MFN1 and MFN2) at the outer mitochondrial membrane ([@bib8]). Mitochondrial dynamics is beginning to emerge as a crucial factor in regulating cell fate ([@bib15], [@bib22], [@bib23]).

Many connections between the mitochondrial dynamics machinery and apoptosis have been made. Apoptosis is mediated by the BCL-2 family of proteins ([@bib21]). When cells are subjected to stress, the mitochondrial network has been shown to undergo DRP-1- and FIS1-mediated fragmentation in a process involving BAX translocation and co-localization with DRP-1 and endophilin B1 ([@bib12], [@bib13], [@bib32]). Previous reports suggested that BAX and BAK could also influence MFN2 function in healthy cells ([@bib14]). The data shown in this report demonstrate that an anti-apoptotic protein belonging to the BCL-2 family, myeloid cell leukemia 1 (MCL-1), is a fundamental regulator of mitochondrial dynamics in human PSCs (hPSCs), independent of its role in apoptosis. MCL-1 is essential for embryonic development and for the survival of various cell types ([@bib31]). Interestingly, recent studies have proposed that MCL-1 may also drive changes in cancer cell metabolic profiles to promote the biosynthesis of substrates needed for proliferation ([@bib2], [@bib27]).

To examine the function of MCL-1 in both undifferentiated and differentiated cells, we took advantage of various features of the hPSC model, including (1) high expression of MCL-1, (2) a predominantly fragmented mitochondrial network, and (3) the ability to induce differentiation into early progenitor stages. This model provided an ideal system to examine not only the potential role of MCL-1 in mitochondrial structure but also its effects on cell fate. Here, we report MCL-1 as a modulator of mitochondrial dynamics in PSCs and demonstrate the value of the stem cell model in studying the plasticity of the mitochondrial network during reprogramming and differentiation.

Results and Discussion {#sec2}
======================

Human Pluripotent Stem Cells Downregulate MCL-1 upon Differentiation {#sec2.1}
--------------------------------------------------------------------

We previously reported that human embryonic stem cells (hESCs) become resistant to DNA damage as differentiation is engaged ([@bib11]). This resistance is in part associated with changes in the activation status of BAX, as well as mitochondrial priming ([@bib11], [@bib20]). We first sought to probe the status of the apoptotic machinery by measuring levels of various BCL-2 family members during differentiation, when this apoptotic resistance is acquired. hESC colonies were grown in suspension in the absence of a matrix layer as aggregates, also known as embryoid bodies (EBs) ([@bib25]). We compared protein expression between hESCs and 3-day EBs by western blot analysis. Since differentiation causes apoptotic resistance, we expected to detect an overall increase in the expression of anti-apoptotic proteins and a decrease in the expression of pro-apoptotic proteins. As expected, the pluripotency transcription factor NANOG was downregulated in EBs, and sirtuin-2 (SIRT2), a NAD^+^-dependent deacetylase, which is induced upon differentiation ([@bib30]), was upregulated. BAX and BCL-XL showed no detectable changes in expression during differentiation, and BCL-2 was significantly upregulated. In stark contrast, MCL-1 was significantly downregulated after only 3 days of differentiation ([Figure 1](#fig1){ref-type="fig"}A). MCL-1 downregulation was also detected in mouse ESC-derived EBs ([Figure S1](#mmc1){ref-type="supplementary-material"}A). As reported previously, these results indicate that BCL-2 may be critical mediator of cell death resistance in early differentiation ([@bib20]). Counterintuitively, MCL-1 does not appear to be a major determinant of the apoptotic resistance characteristic of EBs ([@bib11]).Figure 1hESCs Engage Rapid Apoptosis after DNA Damage, which Can Be Reversed upon Cell Differentiation by MCL-1 Downregulation(A) MCL-1 protein expression is significantly decreased in EBs.(B) hESCs were treated with GX15-070 or ABT-737 ± 20 μM etoposide. Cell survival was quantified each hour after etoposide treatment.(C) GX15-070 treatment of hESCs results in decreased expression of NANOG and OCT4.(D) Immunofluorescence images (63×) show decreased staining for OCT4 (green) when treated with GX15-070. Nuclei: Hoechst 33258. Scale bar, 10 μm.(E) In contrast, increasing treatments of ABT-737 do not affect OCT4 or NANOG protein levels.(F) Treatment of hESCs with 500 nM MIM-1 results in lowered expression of NANOG and OCT4.(G and H) Immunofluorescence (20×) shows decreased expression of NANOG and OCT4. Error bars represent ±SD for three independent experiments. Scale bar, 100 μm.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To determine whether downregulation of MCL-1 was a particular trait of EB formation, we differentiated hESCs into trophoblast-like cells by addition of bone morphogenetic protein 4 (BMP4) and into neural progenitor cells using dual SMAD inhibition, as previously reported ([@bib1], [@bib5]) ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1F). Differentiation to both lineages was accompanied by a significant downregulation of MCL-1 ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D), mimicking the EB formation results. This was unexpected, since EBs, trophoblast-like cells, and neural progenitor cells are more resistant to apoptosis than undifferentiated stem cells ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F).

To probe whether the downregulation of MCL-1 had a functional role in maintaining pluripotency, we examined the effect of inhibiting MCL-1 in hESCs. Cell-permeable, selective small-molecule antagonists of BCL-2, BCL-XL, and MCL-1, known as BH3 mimetics, have been identified ([@bib24]). We first used the pan-BCL-2 inhibitor GX15-070 ([@bib9]), which inhibits BCL-2, BCL-XL, and MCL-1, and compared it with the BH3-only mimetic ABT-737 ([@bib26]), which only inhibits BCL-2 and BCL-XL. Since these small-molecule inhibitors target the main anti-apoptotic proteins, we expected treatment with etoposide in combination with either inhibitor to accelerate cell death onset compared to treatment with only etoposide. Not surprisingly, treatment with ABT-737 increased the sensitivity of hESCs to etoposide-induced DNA damage ([Figure 1](#fig1){ref-type="fig"}B). However, rather unexpectedly, treatment with GX15-070 had the opposite effect and resulted in reduced cell death sensitivity in response to etoposide ([Figure 1](#fig1){ref-type="fig"}B), pointing to a paradoxical effect of MCL-1 inhibition in mediating apoptotic resistance.

These results, together with the observed reduced MCL-1 expression, suggest that MCL-1 inhibition induces a partial protective effect that resembles the decrease in apoptotic sensitivity engaged during differentiation. Consistent with this hypothesis, treatment of hESCs with GX15-070 reduced the expression of pluripotency markers NANOG and OCT4, while treatment with ABT-737 did not affect the expression of these pluripotency factors ([Figures 1](#fig1){ref-type="fig"}C--1E). To confirm the effect of MCL-1 on pluripotency, we then turned to MIM-1, an MCL-1-specific small-molecule inhibitor ([@bib10]), which caused the significant decrease of both NANOG and OCT4 expression ([Figures 1](#fig1){ref-type="fig"}F--1H, [S1](#mmc1){ref-type="supplementary-material"}G, and S1H). SOX2 expression was not affected by MCL-1 inhibition, suggesting that hESCs treated with MIM-1 may be differentiating to the default neuroectoderm lineage. These results indicate that MCL-1 may be necessary for hPSC maintenance of pluripotency.

MCL-1 Is Induced during Reprogramming, and Its Inhibition Causes Changes in the Stem Cell Mitochondrial Network {#sec2.2}
---------------------------------------------------------------------------------------------------------------

We next examined whether MCL-1 expression upregulation was also engaged during the transition to pluripotency. We first reprogrammed human fibroblasts by delivering pluripotency factors using the non-integrating Sendai-based vector system ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Compared with fibroblasts, MCL-1 is expressed at high levels in human induced PSCs (hiPSCs) ([Figure 2](#fig2){ref-type="fig"}A) and hESCs ([Figure 2](#fig2){ref-type="fig"}B), both of which are highly sensitized to cell death ([@bib11]) ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Along with high expression levels of MCL-1, we also observed that iPSCs have a fragmented mitochondrial network when compared with their parent human fibroblast line ([Figure S2](#mmc1){ref-type="supplementary-material"}D), consistent with previous reports suggesting that mitochondria undergo vast changes during reprogramming in response to overexpression of pluripotency factors ([@bib7]).Figure 2MCL-1 Is Highly Expressed in hESCs and Maintains Mitochondrial Fission(A and B) MCL-1 protein expression is increased in hiPSCs (A) and hESCs (B) when compared with human fibroblasts (hFibrob). Bar graphs show quantification of band intensity relative to hFibrob β-actin.(C) hESCs were treated with 500 nM MIM-1, inducing mitochondrial elongation. Cytochrome *c* staining (Cyt c) depicts mitochondria (63×). Scale bar, 10 μm.(D) Quantification of cells with elongated mitochondria in (C).(E and F) MIM-1 treatment (500 nM) in hESCs results in p-DRP-1 S616 downregulation. Band density was quantified relative to control DMSO.All error bars represent ±SD in at least three independent experiments. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

We next investigated whether MCL-1 has a role in the maintenance of mitochondrial dynamics in PSCs. We inhibited MCL-1 in hESCs using MIM-1 and examined its effects on mitochondrial structure. In response to MCL-1 inhibition, the mitochondria appear to fuse and become more elongated, as shown by cytochrome *c* staining ([Figures 2](#fig2){ref-type="fig"}C and 2D). We hypothesized that these changes in mitochondrial shape could be orchestrated through crosstalk between MCL-1 and the proteins involved in mitochondrial dynamics. We first interrogated the expression levels of active DRP-1 in response to MCL-1 inhibition. Phosphorylation of DRP-1 on Ser-616 enhances DRP-1 activity ([@bib33]). Cells treated with MIM-1 displayed downregulated DRP-1 phosphorylation (p-DRP-1 S616) compared with vehicle control cells ([Figures 2](#fig2){ref-type="fig"}E and 2F), providing evidence for a role of MCL-1 in the regulation of DRP-1 activity.

To confirm that the effects of the small-molecule inhibitor MIM-1 were due specifically to MCL-1 inhibition, we performed loss-of-function experiments utilizing an RNAi approach. MCL-1 expression was knocked down in hESCs using small interfering RNA (siRNA). As seen with the small-molecule inhibitors of MCL-1, transmission electron microscopy images confirmed significant elongation of the mitochondria in MCL-1 knockdown hESCs in comparison with scramble siRNA controls ([Figure 3](#fig3){ref-type="fig"}A). Importantly, OCT4 and p-DRP-1 Ser-616 levels were also significantly decreased upon MCL-1 knockdown ([Figures 3](#fig3){ref-type="fig"}B and 3C), as seen in the presence of MIM-1. Therefore, MCL-1 appears to affect pluripotency, at least in part, through the regulation of DRP-1 activity.Figure 3MCL-1 Inhibition Results in Elongated Mitochondria and Low Expression of Active DRP-1(A) Transmission electron microscopy images showing elongated mitochondrial morphology in hESCs after MCL-1 downregulation. Scale bar, 500 nm.(B) Knockdown of MCL-1 results in lowered expression of OCT4 and p-DRP-1 S616.(C) Quantification of western blots (WBs) in (B). Error bars represent ±SD for at least three separate experiments.(D) Representation of murine constructs encoding MCL-1.(E) hESCs were treated with BMP4, then transfected with *Mcl-1*^*WT*^, *Mcl-1*^*OM*^, or *Mcl-1*^*Matrix*^. OCT4 expression was quantitated. Error bars represent ±SD for three independent experiments.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Expression of MCL-1 at the Mitochondrial Matrix Delays Differentiation {#sec2.3}
----------------------------------------------------------------------

It has been shown that MCL-1, besides localizing to the outer mitochondrial membrane, also localizes to the mitochondrial matrix in mouse embryonic fibroblasts and some human cancer lines. The mitochondrial targeting sequence of MCL-1 resides in an N-terminal region that is cleaved from the wild-type form, allowing MCL-1 to be trafficked into the matrix. We investigated the effect of these separate forms of MCL-1 on maintaining pluripotency encoded by three expression vectors ([Figure 3](#fig3){ref-type="fig"}D) ([@bib28]): wild-type *Mcl-1* (*Mcl-1*^WT^), mitochondrial outer membrane-located *Mcl-1* (*Mcl-1*^OM^), and mitochondrial matrix-located *Mcl-1* (*Mcl-1*^Matrix^). MCL-1^WT^ localizes to both the outer mitochondrial membrane and the matrix. MCL-1^OM^ was obtained by mutating the arginine residues at positions 5 and 6 of MCL-1 to alanine. MCL-1^OM^ localizes to the mitochondrial outer membrane, preserving MCL-1 anti-apoptotic function, but it cannot be imported to the mitochondrial matrix. MCL-1^Matrix^ was obtained by fusing the mitochondrial targeting sequence of matrix-localized ATP synthase to N-truncated MCL-1 (lacking the first 66 amino acids). MCL-1^Matrix^ localizes exclusively to the mitochondrial matrix.

Ectopic expression of MCL-1^OM^ showed the expected decrease in OCT4 expression in response to BMP4 ([Figure 3](#fig3){ref-type="fig"}E). Interestingly both MCL-1^WT^ and MCL-1^Matrix^ caused a delay in differentiation in response to BMP4, as shown by a decrease in OCT4-negative cells ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}). These results indicate that MCL-1 may have an alternative function at the mitochondrial matrix in maintaining pluripotency.

MCL-1 Interacts with and Maintains the Stability of DRP-1 and OPA1 {#sec2.4}
------------------------------------------------------------------

To confirm that MCL-1 is in fact localized to the mitochondrial matrix in hPSCs, we co-expressed a GFP-tagged *MCL-1* construct (EGFP-MCL-1) and a DsRed-mito construct, which encodes a truncated form of cytochrome *c* oxidase subunit 2 (COX2) that localizes exclusively to the mitochondrial matrix ([Figure 4](#fig4){ref-type="fig"}A). Line-scan measurements of fluorescence show that MCL-1 co-localizes with the matrix marker, DsRed-mito ([Figure 4](#fig4){ref-type="fig"}B). The localization of MCL-1 at both the outer mitochondrial membrane and at the matrix in stem cells suggests that MCL-1 could be interacting with DRP-1 (at the outer membrane) to promote mitochondrial fragmentation and/or OPA1 (at the matrix) to repress fusion of the mitochondrial network in hESCs.Figure 4MCL-1 Regulates Mitochondrial Dynamics through Interaction with DRP-1 and OPA1(A) hiPSCs expressing EGFP-MCL-1 or control EGFP and DsRed-mito. Scale bar, 2 μm.(B) Fluorescence intensity plots show co-localization of EGFP-MCL-1 and DsRed-mito. Arrow indicates location of the line used for fluorescence intensity by line scan.(C and D) PLA of cells treated for 6 hr with or without 100 nM S63845 (MCL-1*i*). Representative Z-stack images are shown. Red indicates MCL-1:OPA1 (C) and MCL-1:DRP-1 (D) proximity; blue indicates Hoechst 33258. Average puncta/cell was quantitated for at least 300 cells/sample (each sample done in triplicate). Error bars represent ±SEM from three independent experiments, Welch\'s unpaired 2-tailed t test. Scale bar, 10 μm.(E) Western blot of MCL-1 after siRNA-mediated knockdown. At least three independent experiments were quantified. Error bars represent ±SD.(F) Working model of MCL-1 regulation of mitochondrial dynamics.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To test this possibility, we performed co-immunoprecipitation experiments using both total cell fractions and mitochondrial purifications to pull down MCL-1 and check for binding to DRP-1 and OPA1 ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Western blot analysis identified a shifted band roughly 20 kDa larger than the expected DRP-1 band ([Figure S4](#mmc1){ref-type="supplementary-material"}B). We speculate that this could be a modified, active form of DRP-1, presumably due to its phosphorylation and sumoylation when in its active state ([@bib3], [@bib6]). In the total cell fraction, we did not detect binding between MCL-1 and OPA1. However, we detected strong binding in mitochondrial preparations of hESCs ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These *in vitro* biochemical assays suggest that MCL-1 is binding to both DRP-1 and OPA1 in human embryonic stem cells.

We then used a proximity ligation assay (PLA) to confirm binding of these proteins *in situ* ([Figure S4](#mmc1){ref-type="supplementary-material"}C). We first confirmed MCL-1 interaction to the BH3-only protein, BIM. BIM is known to bind MCL-1 by inserting its BH3 domain into MCL-1\'s surface groove ([@bib23]). We detected the expected interaction of MCL-1 and BIM, as indicated by red fluorescent puncta ([Figure S4](#mmc1){ref-type="supplementary-material"}D). We then probed for binding of MCL-1 with both OPA1 and DRP-1. Indeed, as seen in the immunoprecipitation experiments, we detected MCL-1 interaction with OPA1 ([Figure 4](#fig4){ref-type="fig"}C) and DRP-1 ([Figure 4](#fig4){ref-type="fig"}D). We then used a derivative of a recently reported MCL-1 inhibitor, S63845 ([@bib16]), which works by competing for binding to the BH3 domain of MCL-1. We confirmed that S63845 also caused changes to the mitochondrial network ([Figure S4](#mmc1){ref-type="supplementary-material"}E). As expected, S63845 effectively disrupted the interaction between MCL-1 and BIM ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Interestingly, as indicated by the decrease in the number of puncta, S63845 (MCL-1*i*) disrupts interactions with mitochondrial dynamics machinery at both the outer mitochondrial membrane (MCL-1:DRP-1) and the matrix (MCL-1:OPA1) ([Figures 4](#fig4){ref-type="fig"}C and 4D). These results suggest that MCL-1 associates with both GTPases through its characteristic hydrophobic binding groove ([@bib4]).

Previously, we determined that MCL-1 downregulation affected the activity of DRP-1, but not its stability ([Figure 3](#fig3){ref-type="fig"}B). Interestingly, MCL-1 downregulation did cause a significant decrease in OPA1 expression ([Figure 4](#fig4){ref-type="fig"}E), indicating that MCL-1 influences OPA1 stability, but not necessarily its function, since the mitochondria in hESCs are still capable of fusing when MCL-1 is inhibited ([Figure 3](#fig3){ref-type="fig"}A). Mitochondrial fusion is key for efficient assembly of the electron transport chain (ETC). Interestingly, OPA1 has also been implicated in maintaining oxidative phosphorylation in cells. Thus, our results suggest that preventing OPA1 activity (either in fusion or in OXPHOS) could be crucial for maintaining stem cell pluripotency.

Taken together, our findings imply that MCL-1 modulates mitochondrial dynamics and pluripotency through interactions with mitochondrial fission and fusion regulators. Based on our observations, we propose a model in which MCL-1 at the outer mitochondrial membrane regulates cell death and promotes DRP-1 activity and mitochondrial fragmentation ([Figure 4](#fig4){ref-type="fig"}F). Our results with S63845 ([@bib19]) suggest that these interactions are modulated through the MCL-1 BH3 binding groove. It would be interesting to test whether there are two pools of MCL-1, one that is binding to the pro-apoptotic proteins and inhibiting apoptosis and another capable of binding and regulating DRP-1, promoting mitochondrial fragmentation. It will also be necessary to follow up the effects of MCL-1 inhibition-induced mitochondrial changes on the metabolic state of PSCs. In addition, examining the metabolic requirement for MCL-1 during reprogramming could be intriguing in light of recent reports suggesting a multi-stage reprogramming process ([@bib18]).

The process of differentiation into progenitors and committed cells is likely regulated, at least in part, by a shift in dependence to MCL-1 anti-apoptotic activity. It will be crucial to examine MCL-1\'s function in adult stem cells from different tissues. Likewise, identifying the signaling pathways by which mitochondria-nucleus crosstalk occurs upstream and downstream of MCL-1 in stem cells and their progenitors, as has been shown with murine neural progenitor cells ([@bib15]), is an important future direction. By studying the role of MCL-1 in mitochondrial dynamics, we can increase our understanding of the fundamental mechanisms governing pluripotency and self-renewal.

Experimental Procedures {#sec3}
=======================

A detailed description of all methods is included in the [Supplemental Information](#app2){ref-type="sec"}.

Cell Culture {#sec3.1}
------------

H9 hESC line was obtained from WiCell. All experiments with pluripotent stem cells were performed under the supervision of the Vanderbilt Institutional Human Pluripotent Cell Research Oversight (VIHPCRO) Committee. Details of stem cell culture maintenance and treatments are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Transfections {#sec3.2}
-------------

Commercially available siRNA was used to knock down MCL-1 using RNAi max (Thermo Fisher). For overexpression of MCL-1, GFP-tagged MCL-1, and DsRed-mito proteins, Fugene (Promega) was used. Transductions are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Binding Assays {#sec3.3}
--------------

Dynabeads (Invitrogen) were used for immunoprecipitation experiments, and the DuoLink kit (Sigma) was used for PLA.

Immunofluorescence {#sec3.4}
------------------

Cells were fixed with 4% paraformaldehyde and processed as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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